Recent Updates In Pharmacologic And Device Therapy For Peripartum Cardiomyopathy
Mostafa Refaat Hassan Zahran;
Abstract
but the oxygenation status of the patient plays a central role. If the patient is adequately oxygenated, percutaneous [e.g. intra-aortic balloon pump (IABP), Impella®] or surgical (e.g. CentriMag®, AbiomedBVS 5000®) devices can be used to restore circulation. In contrast, in the presence of impaired oxygenation, other devices with integrated oxygenation should be used [e.g. TandemHeart®, veno-arterial extracorporeal membrane oxygenation (ECMO)].
Novel therapies, such as the wearable cardioverter-defibrillator (WCD) (LifeVest®, Zoll, Pittsburgh, PA, USA) are an interesting alternative for the prevention of sudden cardiac death in the first months after diagnosis, until a definitive decision about ICD implantation can be made.
It is a misconception that hope for recovery depends upon improvement or recovery within the first six to 12 months of diagnosis. Many women continue to improve or recover even years after diagnosis with continued medicinal treatment.
Left ventricular recovery and function are considered the most reliable prognostic factors and predictors of survival in subsequent pregnancies. Future pregnancies are not recommended in women with persistent heart failure, because the heart most likely would not be able to tolerate the increased cardiovascular workload associated with the pregnancy.
Novel therapies, such as the wearable cardioverter-defibrillator (WCD) (LifeVest®, Zoll, Pittsburgh, PA, USA) are an interesting alternative for the prevention of sudden cardiac death in the first months after diagnosis, until a definitive decision about ICD implantation can be made.
It is a misconception that hope for recovery depends upon improvement or recovery within the first six to 12 months of diagnosis. Many women continue to improve or recover even years after diagnosis with continued medicinal treatment.
Left ventricular recovery and function are considered the most reliable prognostic factors and predictors of survival in subsequent pregnancies. Future pregnancies are not recommended in women with persistent heart failure, because the heart most likely would not be able to tolerate the increased cardiovascular workload associated with the pregnancy.
Other data
| Title | Recent Updates In Pharmacologic And Device Therapy For Peripartum Cardiomyopathy | Other Titles | التحديثات الأخيرة فى العلاج الدوائي و الأجهزة المستخدمة فى علاج هبوط عضلة القلب فى الفترة المحيطة بالولادة | Authors | Mostafa Refaat Hassan Zahran | Issue Date | 2017 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.